Research map: [ 18 F ] PSMA ‐1007 PET –Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer

Back to the article

Papers in this map

  1. Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer · Anthony Victor D'Amico · 1998 · 4555 citations · Cited by this paper
  2. Editorial Comment on [ 18 F]PSMA‐1007 PET–Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer · Soichiro Yoshida · 2026 · Cites this paper
  3. Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/ DD ) and Pure Urothelial Carcinoma Using a Large‐Scale Japanese Genomic Panel Dataset · 2026 · Related
  4. Natural History of Progression After PSA Elevation Following Radical Prostatectomy · Charles R. Pound · 1999 · 3111 citations · Cited by this paper
  5. Cancer‐Associated Fibroblasts Promote Development of Papillary Renal Cell Carcinoma by Inducing Histone Lactylation of RBM15B to Modify in an m6A ‐Dependent Manner on ANLN · 2026 · Related
  6. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study · Michael S. Hofman · 2020 · 2057 citations · Cited by this paper
  7. Long‐Term Oncologic Outcomes After Laparoscopic Radical Nephroureterectomy: A Contemporary Analysis From a Japanese Multicenter Cohort · 2026 · Related
  8. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer · Ryan Phillips · 2020 · 1179 citations · Cited by this paper
  9. Diabetes Is an Independent Risk Factor for Radiation‐Induced Hematuria After Robotic Stereotactic Body Radiotherapy for Prostate Cancer · 2026 · Related
  10. Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis · Marlon Perera · 2016 · 1021 citations · Cited by this paper
  11. Artificial Intelligence–Based Objective Evaluation of Nerve‐Sparing Status Combined With Preserved Urethral Length Predicts Urinary Continence Recovery After Robot‐Assisted Radical Prostatectomy · 2026 · Related
  12. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy · Matthias J. Eiber · 2015 · 1002 citations · Cited by this paper
  13. Real‐World Outcomes of Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation · 2026 · Related
  14. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis · Marlon Perera · 2019 · 977 citations · Cited by this paper
  15. Efficacy of Testosterone Replacement Therapy Combined With Exercise on Body Composition in Hypogonadal Men · 2026 · Related
  16. Assessment of 68 Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer · Wolfgang P. Fendler · 2019 · 801 citations · Cited by this paper
  17. Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study · 2026 · Related
  18. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients · Frederik Lars Giesel · 2016 · 613 citations · Cited by this paper
  19. Interpreting Sealing‐Device Effects in Retroperitoneal Laparoscopic Adrenalectomy · 2026 · Related
  20. Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study · Michael J. Morris · 2021 · 401 citations · Cited by this paper
  21. Oncological Outcomes and Prognostic Factors of Platinum‐Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum‐Based Chemotherapy Alone: A Propensity Score–Matched Analysis in a Real‐World Population · 2026 · Related
  22. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY) · Kenneth J. Pienta · 2021 · 398 citations · Cited by this paper
  23. Impact of 68 Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis · Sangwon Han · 2018 · 347 citations · Cited by this paper
  24. Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy · Frederik Lars Giesel · 2018 · 340 citations · Cited by this paper
  25. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023) · William Thomas Lowrance · 2023 · 320 citations · Cited by this paper
  26. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer · Stephen J. Freedland · 2023 · 316 citations · Cited by this paper
  27. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy · Christopher J. Kane · 2003 · 275 citations · Cited by this paper
  28. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations · Thomas Van den Broeck · 2019 · 251 citations · Cited by this paper
  29. Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score · Frederik A. Verburg · 2015 · 183 citations · Cited by this paper
  30. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy · Andrea Farolfi · 2018 · 142 citations · Cited by this paper
  31. A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer · Étienne Rousseau · 2019 · 120 citations · Cited by this paper
  32. The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis · Alex Pozdnyakov · 2022 · 83 citations · Cited by this paper
  33. Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer · Clemens Mingels · 2022 · 45 citations · Cited by this paper
  34. High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients · Tadashi Watabe · 2021 · 38 citations · Cited by this paper
  35. PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study · Justin Ferdinandus · 2021 · 37 citations · Cited by this paper
  36. Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer · Niloefar Ahmadi Bidakhvidi · 2021 · 23 citations · Cited by this paper
  37. (18F)-PSMA-1007PET/CT in patients with biochemical recurrence after radical prostatectomy: Diagnostic performance and impact on treatment management · Jia Jiang · 2023 · 9 citations · Cited by this paper
  38. Postoperative early ultrasensitive prostate-specific antigen identifies patients at risk for biochemical recurrence in margin positive prostate cancers: a single-center study · Koji Hatano · 2016 · 4 citations · Cited by this paper
  39. [¹⁸F]PSMA-1007 PET/CT in biochemical recurrence after radical prostatectomy: A single-center experience of detection rate and lesion distribution · Yi Wang · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)